Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

May 23 2023

Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete

By Admin|2023-05-22T20:43:29-04:00May 23rd, 2023|Featured, Investor News, Press Releases|0 Comments

MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate ...

May 9 2023

Halberd Pre-Clinical Test Protocol Approved

By Admin|2023-05-08T18:54:10-04:00May 9th, 2023|Investor News, News, Press Releases|0 Comments

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month End Jackson Center, PA May 9, 2023 – Halberd Corporation (OTC-PINK: "HALB”) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering ...

May 2 2023

Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

By Admin|2023-05-01T20:26:07-04:00May 2nd, 2023|Investor News, Medical, News, Press Releases|0 Comments

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of ...

Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By Admin|2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Apr 17 2023

ICYMI: Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances

By Admin|2023-04-16T18:54:51-04:00April 17th, 2023|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 17, 2023 – Halberd Corporation’s (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN. Professors and student scholar lab assistants are conducting this ...

Mar 30 2023

Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

By Admin|2023-03-29T19:43:38-04:00March 30th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA March 30, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By Admin|2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd’s patented extracorporeal ...

Mar 14 2023

Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens

By Admin|2023-03-14T05:42:44-04:00March 14th, 2023|Featured, Investor News, Medical, Press Releases|0 Comments

Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli ...

Feb 21 2023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

By Admin|2023-02-21T05:34:56-05:00February 21st, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes. Halberd’s patented extracorporeal process and patent-pending ...

Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By Admin|2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Previous 234 Next